Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

SAS Q1 report release date is adjusted

SAS is announcing that the first interim results for the fiscal year 2022 will be released on February 22, 2022 rather than March 1, 2022.SAS has decided to release the report one week early. An investor and analyst webcast will be set up at 10:00 a.m. CET on the release date, and management will be available for interviews by request. For further information, please contact: SAS press office: +46 8 797 29 44 Louise Bergström, VP Investor Relations: +46 70 997 04 93 SAS, Scandinavia’s leading airline, with main hubs in Copenhagen, Oslo and Stockholm, is flying to destinations in

Correction of Press Release: SolarSpring Ships First Solar Powered Drinking Water System to Burkina Faso

In our press release of 28 January on the ECO 3000 system delivery to Burkina Faso, atmosfair gGmbH instead of Eau Propre d’Afrique SARL was wrongly named as the contracting party, which we hereby would like to correct.The last paragraph of the press release states that atmosfair gGmbH had ordered the ECO 3000 system in August 2021, when in fact the investor and operator Eau Propre d´Afrique SARL was the contractor of the system as described correctly in the first section. The earlier press release from August 30th, 2021 also does not state this fact properly. The climate protection

Invitation to telephone conference for Year-end report January – December 2021

Mekonomen’s Year-end report January - December 2021 will be published on Friday, 11 February, at 07:30 a.m CET. A webb conference will be held on the same day at 09:00 a.m CET in English. Mekonomen's CEO Pehr Oscarson and CFO Åsa Källenius will present the results and respond to questions at the English-speaking conference. The presentation material will be available from 8:00 a.m CET on 11 February at www.mekonomen.com under the heading Investors/IR Presentations.   The Conference will be

Puurakentajat's new Board of Directors supports the company's strong growth strategy

Puurakentajat Group Oy Press release 9 February 2022 at 12.15 p.m. EETPuurakentajat Group Oy, the expert in solid wood construction, has nominated three new members to its Board of Directors: Sanna Nokka from Verona Group, Maria Toivanen from Onvest Oy and Pertti Vanhanen from Cromwell Property Group. The new Board of Directors supports the company's strong growth phase and is a continuum to the company’s changed ownership structure, which was implemented in November 2021 when Onvest Oy and Finnish Industry Investment Ltd (Tesi) acquired a stake in Puurakentajat through a directed share

Highlights of Stadshypotek’s Annual Report 2021

JANUARY–DECEMBER 2021 COMPARED WITH JANUARY–DECEMBER 2020 Stadshypotek’s operating profit increased by SEK 236m, or 2%, to SEK 13,077m (12,841). Net interest income grew by SEK 308m to SEK 14,948m (14,640), mainly due to higher lending volumes to the private and corporate markets in Sweden. Of the net interest income, SEK 1,080m (924) was attributable to the branch in Norway, SEK 554m (476) to the branch in Finland and SEK 501m (517) to the branch in Denmark. Excluding the branches, net interest income increased by SEK 90m (489). Net gains/losses on financial transactions increased by

DNB Markets - Nelly: Profitability from Q2e

Nelly reported Q4 sales 1% above our forecast but EBIT SEK2m below. However, we are more optimistic about the sales growth and EBIT margin trend following upbeat management comments on the near-term outlook. As a result, we have raised our fair value to SEK35–45/share (SEK30–40).Q4 results. Sales of SEK407m (1.2% above our forecast of SEK402m) were driven by 9% growth in the core Nordic operations, in part due to more customers. Gross profit of SEK177m (1% below our forecast of SEK179m) was affected by cost inflation and supply-chain disruptions. Nelly reported a gross margin of 43.4% (

The Nomination Committee's proposal to the Board prior to the 2022 Annual General Meeting includes a key player in the diabetes market

The Nomination Committee of Brighter AB (publ) proposes Johnny Ludvigsson, one of the world's top ten experts and researchers on type 1 diabetes, as a new board member of Brighter AB. Johnny Ludvigsson is a Swedish doctor and professor of pediatrics at Linköping University, chief physician at the Children and Women's Center at the University Hospital in Linköping and founder of the Child Diabetes Foundation. With his worldwide network of contacts and extensive experience and expertise, Ludvigsson is expected to be a significant asset for Brighter in its continued work to create solutions

Metsä Board’s co-creation workshop results in an innovative insect hotel

Metsä Board Corporation press release 9.2.2022Finnish Golf Coat Oy is launching a new golf ball packaging that, when empty, takes on a second life as an insect hotel. The innovative packaging is a result of a co-creation workshop organised by Metsä Board, part of Metsä Group. The workshops are part of Metsä Board’s 360 Services that cover the whole packaging value chain by utilising the state-of-the-art Excellence Centre in Äänekoski, Finland. The design of the golf ball packaging was a collaboration involving a packaging design agency, Metsä Board's own packaging design team, the packaging

Attana and AroCell initiates discussion for collaboration

Attana can today announce that the company has initiated a discussion about a new collaboration with the in vitro diagnostics company AroCell AB (Publ).AroCell AB is a Swedish company that develops and markets blood and urine sample tests and specializes in oncology and bacteriology. The company has a broad product portfolio that is used in healthcare and is established in various markets. The collaboration aims to exchange valuable knowledge in quality and product development, while AroCell's biomarkers can eventually be used on Attana's instruments. Teodor Aastrup, CEO Attana comments:

instagrid: The Expert for Mobile High-Performance Battery Systems Raises 33 Million U.S. Dollars

· Instagrid, the Ludwigsburg-based off-grid battery expert, raises $33 million in a Series B financing round · The technology offers mobile power supply from renewable sources that is entirely disconnected from the power grid · Climate tech investor Energy Impact Partners led the financing round · This funding will drive the international expansion of the company and the development of new, scalable business modelsLudwigsburg, 09.02.2022 - instagrid , a leader in high-performance mobile battery systems in the professional sector,  announced today its Series

Silenta Extreme wins "Innovative Product Award" at the Golden Plumb International Building Catalog Awards

GF Hakan Plastik has been awarded the "Innovative Product in Construction Building Catalog Special Award" for its GF Silenta Extreme piping system at the 27[th] annual "Golden Plumb International Building Catalog Awards" organized by YAPI KATALOĞU.YAPI KATALOĞU is Turkey's first and only material catalog that has been in publication since 1973. Their Golden Plumb International Awards ("ALTIN ÇEKÜL Uluslararası Yapı Kataloğu Ödülleri") were given out in three main categories: for innovative products, legal ideas and industry marketing.  GF Hakan Plastik has been providing top-quality

Reltime – Just received their crypto license for the PoA BaaS platform

Oslo, Norway, Feb. 9, 2022 -- Reltime PoA BaaS Ecosystem just received their crypto license in El Salvador to be able to hold digital assets for their client.Reltime.com, a Norwegian and Salvadorean-based challenging BaaS provider is the first of its kind to accomplish that status, what now is “textually considered” a Bitcoin provider for the Republic of El Salvador in the registry of The Central Bank of El Salvador. Reltime is very bullish and supportive of the movement of El Salvador.  The Regulations of the Law establishes that Reltime has license to provide for itself or for third

NOTIFICATION OF MANAGERS’ AND CLOSELY RELATED PARTIES’ TRANSACTIONS WITH DAMPSKIBSSELSKABET NORDEN A/S’ SHARES IN CONNECTION WITH SHARE BUY-BACK PROGRAM

ANNOUNCEMENT NO. 35 - 9 FEBRUARY 2022 In connection with the announced share buy-back program in Dampskibsselskabet NORDEN A/S, A/S Motortramp participates by selling shares pro rata in order to maintain the current ownership of just under 32% of the shares in Dampskibsselskabet NORDEN A/S. The market will be informed accordingly – see the attached file and announcement no. 75/2021. Kind regards, Dampskibsselskabet NORDEN A/S Martin Badsted CFO For further information:Thomas France, Investor Communications Partner, tel.: 3315 0451

Complement: RhoVac plans for a fully guaranteed convertible loan rights issue, to finance activities following a successful clinical phase IIb study outcome

Complement: appendix added to previous release. RhoVac AB (”RhoVac”) announces today, February 9, 2022, that the Board of Directors intends to decide on execution of a preferential rights issue of a convertible loan (“the Planned Offer”) of approx. 25 M SEK in March/April 2022. The Planned Offer is via written agreement fully guaranteed, free of charge, by RhoVac’s largest shareholder M2 Asset Management AB. The objective of the Planned Offer is to further ensure that the company, given positive primary outcome results of the study, has the proper financial strength to negotiate and conclude

Selvaag Bolig ASA: Invitation to presentation of fourth quarter 2021 results

Selvaag Bolig ASA will publish its fourth quarter 2021 results Tuesday 15 February at 07:00 am CET. The quarterly report and the presentation materials will be available on the company's website, www.selvaagboligasa.no/en and www.newsweb.no, as well as news wires. CEO Sverre Molvik and CFO Christopher Brunvoll will present the company's results at 08:30 am CET at Høyres Hus, Stortingsgaten 20 in Oslo. A light breakfast will be served from 08:00. The presentation will be held in Norwegian and transferred via live webcast. Link to the webcast. 

Irisity recruits Johan Höglund as new CGO.

Irisity AB (publ), leading AI video analytics provider, continue to strengthen its management with the appointment of Johan Höglund as Chief Growth Officer, CGOAccelerating our international expansion, with ever larger global deals and partnerships, the appointment of Johan Höglund now strengthen our business development capabilities and growth. “Johan Höglund is a well-recognized and accomplished senior level professional, with an impressive track record of constantly delivering results. He now brings this experience to Irisity, being well suited overseeing our continued rapid growth”,

AFRY to design sustainable textile fibre biofactory for Altri in Spain

Altri has awarded AFRY engineering, site selection and integrated environmental authorization services assignment for a greenfield textile fiber factory in Spain. In addition, AFRY will support Altri to conceive, create and implement foundations for Industry 4.0 technologies in this new plant.The demand for sustainable textile fibres is growing quickly globally. To support this growth, the Portuguese pulp producer Altri has become the industrial partner to public-private consortium Impulsa (Society for the Development of Strategic Projects of Galicia) as the lead investor and technologist

Qt framework used for the development of Stellantis’ newly launched in-vehicle HMI

Qt has been selected to add 3D effects and enhance the human-machine interface across its portfolio of iconic European automotive brands.Espoo, Finland – 9[th] February 2022 – The Qt Company , the leading global provider of software technology, announces that Stellantis , the global automaker and provider of innovative mobility solutions works with Qt for the development of their current in-vehicle HMI systems across its portfolio of iconic European car brands. The project, which began in 2018, will see the Qt technology used for the

DanCann Pharma A/S has submitted application to the Danish Medicines Agency for EU-GMP-approval for Biotech Pharm1

COPENHAGEN, Denmark, 9 February 2022 – DanCann Pharma A/S (SS: DANCAN) (“DanCann Pharma” or the “Company”), a Danish company powered by cannabinoids, hereby announce that the Company submitted its application for EU-GMP-approval to the Danish Medicines Agency.In April, DanCann Pharma pressed the start button in the Company’s first production facility, Biotech Pharm1 in Ansager. Now the Company is ready to be inspected from the Danish Medicines Agency in order to be approved according to EU-GMP standards. The approval is expected to be in place by the half year of 2022. Biotech Pharm1 is

Invitation to presentation of Embracer Group’s Q3 report

Embracer Group hereby invites you to a presentation in connection with the publication of the interim report for the third quarter, the period October-December 2021. The report will be published at 06.00 (CET) on February 17th and available as of this time at: www.embracer.comThe presentation will be held in English by CEO Lars Wingefors and CFO Johan Ekström, and afterwards a Q&A session will follow, led by analyst Oscar Erixon from Carnegie. Date:           February 17, 2022 Time:          09:00 CET Location:     Karlstad CCC, Tage Erlandergatan 8, Karlstad Online:

Mandatory notification of trade

On February 8, primary insiders in Atea ASA completed the following transactions. Robert Giori sold 83,400 shares and entered a contract to purchase 83,660 shares. Robert Giori sold 83,400 shares at an average price of 140.15.  On the same day, he exercised 100,000 stock options in the company at an average strike price of NOK 92.00.  Following withholding of income taxes, he acquired 83,660 shares in the company through the exercise of options.  The shares will be transferred on February 9. After the transactions, Robert Giori owns 126,587 shares together with close associates, and

Transactions in connection with share buy-back programme

On 4 March 2021, H+H International A/S (hereinafter referred to as “H+H” or “the Company”) initiated a share buy-back programme in compliance with Article 5 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on Market Abuse and Commission Delegated Regulation (EU) 1052/2016 of 8 March 2016 (the “Safe Harbour Regulation”). On 18 March 2021, the share buy-back programme was increased by DKK 15 million, thereby increasing the maximum aggregate purchase price of the shares to be bought back under the programme to DKK 115 million. The share buy-back

RhoVac plans for a fully guaranteed convertible loan rights issue, to finance activities following a successful clinical phase IIb study outcome

RhoVac AB (”RhoVac”) announces today, February 9, 2022, that the Board of Directors intends to decide on execution of a preferential rights issue of a convertible loan (“the Planned Offer”) of approx. 25 M SEK in March/April 2022. The Planned Offer is via written agreement fully guaranteed, free of charge, by RhoVac’s largest shareholder M2 Asset Management AB. The objective of the Planned Offer is to further ensure that the company, given positive primary outcome results of the study, has the proper financial strength to negotiate and conclude optimally on the clinical phase IIb study follow-

BioStock: Evaxion Biotech publishes EVX-01 data in scientific journal OncoImmunology

This past decade has seen the rise of immunotherapies for the treatment of cancer, in many ways revolutionising this enormous treatment field. Danish Evaxion Biotech aims at pushing this development even further with its AI-powered personalised approach. The company recently published results from an ongoing phase I/IIa clinical study with lead drug candidate EVX-01 in the open access, peer-reviewed clinical journal OncoImmunology.Read the full article at biostock.se:https://www.biostock.se/en/2022/02/evaxion-biotech-publishes-evx-01-data-in-scientific-journal-oncoimmunology/This is a

There are no items matching the current filter
There are no more items matching the current filter
Back to top